Jan 9, 2024 7:00am EST Tonix Pharmaceuticals Presents Additional Data Highlighting the Favorable Tolerability and Differentiated Side Effect Profile of TNX-102 SL in Second Positive Phase 3 Clinical Trial for the Management of Fibromyalgia
Jan 3, 2024 7:00am EST Tonix Pharmaceuticals to Present at Two Upcoming Investor Conferences in January: Focus is on TNX-102 SL for the Management of Fibromyalgia Following Positive Topline Results in Second Pivotal Phase 3 Trial
Dec 20, 2023 10:35am EST Tonix Pharmaceuticals Announces Registered Direct Offering of up to $144 Million
Dec 20, 2023 10:30am EST Tonix Pharmaceuticals Announces Highly Statistically Significant and Clinically Meaningful Topline Results in Second Positive Phase 3 Clinical Trial of TNX-102 SL for the Management of Fibromyalgia
Dec 11, 2023 7:00am EST Tonix Pharmaceuticals to Present at The National Academies Committee on the Current State of Research, Development, and Stockpiling of Smallpox Medical Countermeasures Public Meeting
Dec 4, 2023 7:00am EST Tonix Pharmaceuticals Announces IND Clearance by the FDA for Phase 2 Trial of TNX-2900 for the Treatment of Prader-Willi Syndrome, the Most Common Genetic Cause of Life-Threatening Childhood Obesity
Nov 28, 2023 7:00am EST Tonix Pharmaceuticals to Present at Two Upcoming Investor Conferences in December
Nov 15, 2023 7:00am EST Tonix Pharmaceuticals Completes Clinical Stage of Phase 3 RESILIENT Study of TNX-102 SL for the Management of Fibromyalgia
Nov 13, 2023 7:00am EST Tonix Pharmaceuticals Announces Enrollment Initiated in Mass General Brigham Phase 2 Investigator-Initiated Study of TNX-1900 (Intranasal Potentiated Oxytocin) for Bone Health in Children with Autism Spectrum Disorder
Nov 9, 2023 4:15pm EST Tonix Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Highlights
